Literature DB >> 4025687

Eighteen-month follow-up on the treatment of urinary schistosomiasis with a single dose of metrifonate.

S A Tswana, P R Mason.   

Abstract

Egg excretion of school children with urinary schistosomiasis treated with a single 10 mg/kg dose of metrifonate was monitored over a period of 18 months. At 18 months 68.8% of infected children showed a greater than 90% reduction in egg excretion and 23.7% had ceased excreting eggs. During the study period 25% of children with no evidence of infection at the start of the trial had become infected, while 45.5% of children apparently cured by the metrifonate treatment had recommenced egg excretion. The evidence suggested that reinfection rather than recovery of adult worms was responsible. Children with scanty or light infections, in general, showed increasing egg excretion rates during the following period, while those with heavy or severe infections showed a sustained reduction. In view of this, single dose metrifonate may be a useful approach to mass treatment in a schistosomiasis control program, resulting in significant reduction in egg excretion in those most likely to be important sources of transmission.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4025687     DOI: 10.4269/ajtmh.1985.34.746

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  3 in total

1.  A simplified dosage schedule of metrifonate in the treatment of Schistosoma haematobium infection in Somalia.

Authors:  Y Aden-Abdi; L L Gustafsson; S A Elmi
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Metrifonate in the control of urinary schistosomiasis in Zanzibar.

Authors:  A F Mgeni; U M Kisumku; F S McCullough; H Dixon; S S Yoon; K E Mott
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

3.  Field trial of the efficacy of a simplified and standard metrifonate treatments of Schistosoma haematobium.

Authors:  Y Aden Abdi; L L Gustafsson
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.